Finance

Lists
Why is SGIOY up ४.१०%?
Dive Deeper
SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
US$ ९.१३
+४.१०%
(+०.३६) 1D
अक्टोबर १५, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGIOY...
Open
US$ ९.५३
High
US$ ९.५३
Low
US$ ८.९५
Mkt. cap
२६.१० खरब
Avg. vol.
१.७३ लाख
Volume
१.२० लाख
52-wk high
US$ १२.००
52-wk low
US$ ७.८३
Beta
०.०७
Shares outstanding
१.७८ अरब
No. of employees
६ हजार
Open
US$ ९.५३
High
US$ ९.५३
Low
US$ ८.९५
Mkt. cap
२६.१० खरब
Avg. vol.
१.७३ लाख
Volume
१.२० लाख
52-wk high
US$ १२.००
52-wk low
US$ ७.८३
Beta
०.०७
Shares outstanding
१.७८ अरब
No. of employees
६ हजार
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
१५ घण्टा पहिले
Jefferies sets JPY 3,900.00 target for Shionogi stock
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi 2 ADR Representing 1 Ord Shs
CEOIsao Teshirogi
Employees६.२२ हजार
Founded१८७८
Headquarters-
Sector-
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
१.१३ खरब
१.४८ खरब
१.३९ खरब
१.६३ खरब
Cost of goods sold
१६.९४ अरब
२५.०९ अरब
२८.१० अरब
३०.८० अरब
Cost of revenue
१६.९४ अरब
२५.०९ अरब
२८.१० अरब
३०.८० अरब
Research and development expenses
२७.५५ अरब
२९.८७ अरब
४०.५४ अरब
३१.७९ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२७.५६ अरब
३५.२७ अरब
३२.९२ अरब
४४.३६ अरब
Operating expense
५६.५७ अरब
४८.४५ अरब
१.०० खरब
१.१४ खरब
Total operating expenses
७३.५१ अरब
७३.५४ अरब
१.२८ खरब
१.४५ खरब
Operating income
३९.६७ अरब
७४.१८ अरब
१०.८३ अरब
१८.६४ अरब
Other non operating income
-
-१०.०० लाख
७.३१ अरब
-२०.०० लाख
EBT including unusual items
५२.०६ अरब
९२.८९ अरब
४७.६४ अरब
७३.७४ अरब
EBT excluding unusual items
५२.०६ अरब
९३.१० अरब
४७.८० अरब
२५.४७ अरब
Income tax expense
७.८७ अरब
१८.२१ अरब
-५.६० करोड
-२३.९८ अरब
Effective tax rate
१५.१२%
१९.६०%
-०.१२%
-३२.५२%
Other operating expenses
९७.९० करोड
-१७.२५ अरब
१५.४४ अरब
२१.९० अरब
Net income
४४.१९ अरब
७४.६८ अरब
४६.९३ अरब
९७.७० अरब
Net profit margin
३९.०४%
५०.५६%
३३.७७%
५९.८२%
Earnings per share
-
-
-
-
Interest and investment income
१४.२१ अरब
२०.५३ अरब
२३.७३ अरब
१२.१५ अरब
Interest expense
-१.८२ अरब
-१.६१ अरब
-
-५.३२ अरब
Net interest expenses
१२.३८ अरब
१८.९२ अरब
२३.७३ अरब
६.८२ अरब
Depreciation and amortization charges
-४८.५० करोड
-
-१.५३ अरब
-
EBITDA
४४.८३ अरब
८०.२१ अरब
२१.५९ अरब
३९.५२ अरब
Gain or loss from assets sale
-
-
३५.०४ अरब
-
AI content may include mistakes. Learn more
Google एपहरू